Alliances & Partnerships
Glide Pharma’s proprietary Glide technology offers new options in drug formulation that improve the efficacy of drug and vaccine delivery and enhance the therapeutic experience of both patients and carers.
At Glide Pharma we have an open and progressive approach to working with our partners. Focused on a shared product vision, we strive to develop the best possible solutions to meet the therapeutic needs of healthcare professionals and patients.
Glide Pharma conducts formulation development as well as manufacturing and supply of finished products, thus allowing partners to enter into relationships without large capital outlay during early clinical development. Glide Pharma formulates the partner’s drug into a solid dosage form suitable for injection with the needle-free Glide SDI technology. The ability to inject drugs as solids offers pharmaceutical companies a valuable new option for drug delivery, providing a stable, controllable and clean mechanism to deliver drugs and vaccines directly into the body’s tissues.
Building on our partnering success to date, we are actively seeking to work with organizations that recognize the competitive advantages of the Glide technology, for example for the delivery of biologics or for the re-formulation of existing and proven drugs. Opportunities exist not only to partner Glide Pharma’s own product development projects, but also for accessing the technology for co-developing proprietary or generic drugs of your choice.
Glide Pharma is engaged in a number of collaborations and funded feasibility studies with pharmaceutical and large biotech partners.
For further information and if you’d like to explore the opportunity to work with Glide Pharma please contact:
Dr Charles Potter
Chief Executive Officer
charles.potter@glidepharma.com
+44 (0)8700 853700
Register to receive Glide Pharma press releases, updates and newsletters by e-mail.
